Celavie Biosciences

What Celavie Biosciences does

Celavie Biosciences is a privately held biotechnology research company headquartered in Oxnard, California. Founded in 2006, the firm operates with a very small team of 1-10 employees under the continued leadership of founder and CEO Sandy Solmon. Beyond these firmographic facts, no further detail is available in the input data regarding the company's therapeutic focus, scientific platform, pipeline, or intellectual property position.

The company's core products, underlying technology, and go-to-market mechanics are not disclosed in the available sources. No funding rounds, partnerships, customers, contract vehicles, or commercial milestones are documented. Revenue model, pricing mechanics, and customer segmentation are similarly absent, leaving the business model effectively opaque from a third-party diligence perspective. The firm does not appear to maintain a public product portfolio, distribution channels, or named institutional collaborators in the supplied material.

Over a nearly twenty-year operating history, the company has maintained a minimal operational footprint, with no evidence of headcount scaling, institutional capital raises, or commercial partnerships surfaced in the input. This profile is consistent with a founder-led, lean-stage biotechnology research operation, though specific scientific direction, pipeline assets, and revenue status cannot be confirmed from the sources provided. The absence of disclosed activity, funding events, or named personnel beyond the founder represents a material information gap for any prospective investor or acquirer.

Name

Celavie Biosciences

Website

https://celavie.com

Company type

Private

Founded year

2006

Headcount range

1–10 employees

Short description

Celavie Biosciences is a privately held biotechnology research company founded in 2006 and based in Oxnard, California. Operating with a small team under founder-CEO Sandy Solmon, the firm maintains no disclosed product, pipeline, funding, or commercial customer detail in the available data.

Ownership category

akta.pro rank

Product category

Biotechnology Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

akta.pro secondary industry

Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF)

Keywords

• Biotechnology research
• Life sciences research
• Biomedical development
• Cell-based research
• Therapeutic research

Headquarters

HQ city

Oxnard

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Celavie Biosciences is a privately held biotechnology research company that conducts life-sciences research activities. Specific product lines, therapeutic candidates, or research programs are not detailed in the available source material.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Broad incumbents

• IQVIA: Global clinical research services and life sciences analytics firm. Comparable as a broad research services incumbent in the life sciences R&D ecosystem.
• Charles River Laboratories: Large CRO offering discovery, safety assessment, and biopharma manufacturing services. Comparable as a broad incumbent in the contract biology/biopharma research services space where Celavie would compete if it offers research services.
• WuXi AppTec: Global CRO/CDMO with extensive discovery, preclinical, and biologics manufacturing capabilities. Comparable as a broad incumbent in outsourced biotech research and development services.
• Bio-Techne: Developer and manufacturer of high-quality purified proteins and reagents, with a focus on supporting academic and biopharma R&D. Comparable in serving life-science research customers with biological tools and reagents.
• Medpace: Mid-to-large CRO providing clinical and preclinical research services to biopharma. Comparable as an established research services provider in the life-sciences value chain.
• GenScript: Biotechnology tools and services company offering gene synthesis, peptide/protein services, and cell therapy support. Comparable as a life-sciences research services and synthetic biology-adjacent platform.
• ATCC: Nonprofit biological resource center providing authenticated cell lines, microorganisms, and biological materials to researchers. Comparable as a supplier of standardized biological inputs used by life-sciences R&D teams.

Emerging players

• Synthego: Specialized provider of synthetic RNA, CRISPR tools, and genome engineering services for research and therapeutic customers. Comparable as a focused biotech tools/services company in the synthetic biology-adjacent research market.

Market position

Strengths2 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights3 records

Customer concentration

• LinkedInlinkedin.com/company/celavie-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celavie Biosciences